Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 97

    1.

    Risk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor α-blockers: a case-control study.

    Gilson M, Gossec L, Mariette X, Gherissi D, Guyot MH, Berthelot JM, Wendling D, Michelet C, Dellamonica P, Tubach F, Dougados M, Salmon D.

    Arthritis Res Ther. 2010;12(4):R145. Epub 2010 Jul 16.

    PMID:
    20637100
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    2.

    Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry.

    Mariette X, Tubach F, Bagheri H, Bardet M, Berthelot JM, Gaudin P, Heresbach D, Martin A, Schaeverbeke T, Salmon D, Lemann M, Hermine O, Raphael M, Ravaud P.

    Ann Rheum Dis. 2010 Feb;69(2):400-8. Epub 2009 Oct 14.

    PMID:
    19828563
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    3.

    Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients.

    Salliot C, Gossec L, Ruyssen-Witrand A, Luc M, Duclos M, Guignard S, Dougados M.

    Rheumatology (Oxford). 2007 Feb;46(2):327-34. Epub 2006 Jul 31.

    PMID:
    16880188
    [PubMed - indexed for MEDLINE]
    Free Article
    4.

    Listeria monocytogenes infection in patients with rheumatic diseases on TNF-alpha antagonist therapy: the Spanish Study Group experience.

    Peña-Sagredo JL, Hernández MV, Fernandez-Llanio N, Giménez-Ubeda E, Muñoz-Fernandez S, Ortiz A, Gonzalez-Gay MA, Fariñas MC; Biobadaser group.

    Clin Exp Rheumatol. 2008 Sep-Oct;26(5):854-9.

    PMID:
    19032819
    [PubMed - indexed for MEDLINE]
    5.

    Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry.

    Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Bréban M, Pallot-Prades B, Pouplin S, Sacchi A, Chichemanian RM, Bretagne S, Emilie D, Lemann M, Lortholary O, Mariette X; Research Axed on Tolerance of Biotherapies Group.

    Arthritis Rheum. 2009 Jul;60(7):1884-94. Erratum in: Arthritis Rheum. 2009 Aug;60(8):2540. Lorthololary, O [corrected to Lortholary, O].

    PMID:
    19565495
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    6.

    Frequency and tolerance of antituberculosis treatment according to national guidelines for prevention of risk of tuberculosis due to tumor necrosis factor blocker treatment.

    Bray MG, Poulain C, Dougados M, Gossec L.

    Joint Bone Spine. 2010 Mar;77(2):135-41. Epub 2010 Jan 25.

    PMID:
    20097592
    [PubMed - indexed for MEDLINE]
    7.

    Use of the T-SPOT.TB assay to detect latent tuberculosis infection among rheumatic disease patients on immunosuppressive therapy.

    Behar SM, Shin DS, Maier A, Coblyn J, Helfgott S, Weinblatt ME.

    J Rheumatol. 2009 Mar;36(3):546-51. Epub 2009 Feb 17.

    PMID:
    19228655
    [PubMed - indexed for MEDLINE]
    8.

    Serious infections associated with anticytokine therapies in the rheumatic diseases.

    Giles JT, Bathon JM.

    J Intensive Care Med. 2004 Nov-Dec;19(6):320-34. Review.

    PMID:
    15523118
    [PubMed - indexed for MEDLINE]
    9.

    Non-typhi Salmonella infection in patients with rheumatic diseases on TNF-alpha antagonist therapy.

    Peña-Sagredo JL, Fariñas MC, Perez-Zafrilla B, Cruz-Valenciano A, Crespo M, Joven-Ibañez B, Riera E, Manero-Ruiz FJ, Chalmeta I, Hernández MV, Rodríguez-Gómez M, Maíz O, López R, Cobo T, Pita J, Carmona L, Gonzalez-Gay MA; BIOBADASER and EMECAR Groups.

    Clin Exp Rheumatol. 2009 Nov-Dec;27(6):920-5.

    PMID:
    20149306
    [PubMed - indexed for MEDLINE]
    10.

    Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists.

    Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, Saag M, Shatin D, Saag KG.

    Arthritis Rheum. 2007 Apr;56(4):1125-33.

    PMID:
    17393394
    [PubMed - indexed for MEDLINE]
    Free Article
    11.

    Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers.

    Ruyssen-Witrand A, Gossec L, Salliot C, Luc M, Duclos M, Guignard S, Dougados M.

    Clin Exp Rheumatol. 2007 May-Jun;25(3):430-6.

    PMID:
    17631740
    [PubMed - indexed for MEDLINE]
    12.

    Risk of tuberculosis in patients with rheumatoid arthritis in Hong Kong--the role of TNF blockers in an area of high tuberculosis burden.

    Tam LS, Leung CC, Ying SK, Lee GK, Yim CW, Leung YY, Kun EW, Wong KK, Li EK.

    Clin Exp Rheumatol. 2010 Sep-Oct;28(5):679-85. Epub 2010 Oct 22.

    PMID:
    20822708
    [PubMed - indexed for MEDLINE]
    13.

    Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists.

    García-Doval I, Pérez-Zafrilla B, Descalzo MA, Roselló R, Hernández MV, Gómez-Reino JJ, Carmona L; BIOBADASER 2.0 Study Group.

    Ann Rheum Dis. 2010 Oct;69(10):1751-5. Epub 2010 Jun 15.

    PMID:
    20551153
    [PubMed - indexed for MEDLINE]
    14.

    Biologic agents in the treatment of rheumatic diseases with chronic viral infection. Where are we?

    Wendling D, Di Martino V, Herbein G.

    J Rheumatol. 2009 Jun;36(6):1107-8. No abstract available.

    PMID:
    19509089
    [PubMed - indexed for MEDLINE]
    15.

    Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists.

    Lee HH, Song IH, Friedrich M, Gauliard A, Detert J, Röwert J, Audring H, Kary S, Burmester GR, Sterry W, Worm M.

    Br J Dermatol. 2007 Mar;156(3):486-91.

    PMID:
    17300238
    [PubMed - indexed for MEDLINE]
    16.

    The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.

    Suwannalai P, Auethavekiat P, Udomsubpayakul U, Janvitayanujit S.

    Int J Rheum Dis. 2009 Jul;12(2):118-24.

    PMID:
    20374328
    [PubMed - indexed for MEDLINE]
    17.

    Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.

    Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lémann M, Cosnes J, Hébuterne X, Cortot A, Bouhnik Y, Gendre JP, Simon T, Maynadié M, Hermine O, Faivre J, Carrat F; CESAME Study Group.

    Lancet. 2009 Nov 7;374(9701):1617-25.

    PMID:
    19837455
    [PubMed - indexed for MEDLINE]
    18.

    Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature.

    Zingarelli S, Frassi M, Bazzani C, Scarsi M, Puoti M, Airò P.

    J Rheumatol. 2009 Jun;36(6):1188-94. Epub 2009 May 15. Review.

    PMID:
    19447932
    [PubMed - indexed for MEDLINE]
    19.

    Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection.

    Gómez-Reino JJ, Carmona L, Angel Descalzo M; Biobadaser Group.

    Arthritis Rheum. 2007 Jun 15;57(5):756-61.

    PMID:
    17530674
    [PubMed - indexed for MEDLINE]
    Free Article
    20.

    Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry.

    Salmon-Ceron D, Tubach F, Lortholary O, Chosidow O, Bretagne S, Nicolas N, Cuillerier E, Fautrel B, Michelet C, Morel J, Puéchal X, Wendling D, Lemann M, Ravaud P, Mariette X; RATIO group.

    Ann Rheum Dis. 2011 Apr;70(4):616-23. Epub 2010 Dec 21.

    PMID:
    21177290
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk